Aily Labs announced a partnership with Google Cloud to launch its AI Decision Intelligence platform on the Google Cloud Marketplace, allowing pharmaceutical and biotech companies to buy and deploy AI agents directly through existing Google Cloud contracts without extra vendor or compliance reviews.
The platform features a centralized "Super Agent" that coordinates thousands of domain-specific AI sub-agents across research, clinical development, regulatory work, manufacturing, and sales—addressing fragmentation across life sciences enterprises' disconnected IT systems.
What happened
Aily Labs, an AI Decision Intelligence platform company, partnered with Google Cloud to make its platform available on the Google Cloud Marketplace. The move lets pharmaceutical and biotech firms buy Aily's AI agents directly through existing Google Cloud contracts, and those purchases count toward their committed cloud spend without triggering separate vendor reviews or new security evaluations.
Why it matters
Pharma and biotech companies typically juggle R&D, clinical trials, regulatory compliance, and supply chains across dozens of disconnected systems—delays in trial site selection, drug candidate prioritization, and inventory decisions often result. By offering Aily's platform through Google Cloud, enterprises can tap AI agents for drug development and regulatory work without extra procurement friction or security audits.
What to watch
Aily's "Super Agent" orchestrates thousands of specialized AI sub-agents across R&D, clinical development, regulatory filings, capital allocation, supply chain, and commercial operations—all accessible via the Agent Gallery within Gemini Enterprise, Google Cloud's enterprise AI application.
Ask the AI about this article →
Pharmaceutical and biotech enterprises operate across fragmented systems—R&D databases, clinical trial management, regulatory portals, and supply chain software often sit in isolated silos. This fragmentation creates operational delays when insights needed for drug candidate prioritization or trial site selection remain trapped in retrospective reports. Meanwhile, traditional enterprise AI deployments face delays from lengthy security audits, vendor onboarding, and contract negotiations, further slowing the journey from data to decision. Aily Labs' partnership with Google Cloud directly addresses both friction points. By placing the platform on Google Cloud Marketplace, the partnership allows companies already committed to Google Cloud to buy and deploy Aily's agents without new vendor vetting or security reviews—expenditures simply count toward existing cloud commitments. The integration into Gemini Enterprise's Agent Gallery further simplifies deployment, connecting Aily's specialized sub-agents to Google's foundation models and BigQuery data pipelines so that pharmaceutical teams can reason across their fragmented data in a single orchestrated interface.
AI-summarized, only the topics you pick — one digest a day via Email, Slack, or Discord.
Free · takes 30 seconds · unsubscribe anytime
Ask AI anything about this article. Q&As are published on this page for other readers too.
Apple is laying off staff in its Vision team as part of a strategic shift away from VR headsets toward AI-driv…
HP Korea has formed a partnership with Upstage, a large language model (LLM) startup, to advance its localized…
DIGITIMES analyst Joyce Chen stated on August 20 at a semiconductor industry forum in Taipei that optical comm…
At the "AI on Chips: Semiconductor Industry Trends Forum" hosted by DIGITIMES, industry experts highlighted th…
JCET Group posted record first-half 2026 revenue, driven by demand from artificial intelligence infrastructure…
Scott Ortkiese, CEO of Faulkner Capital Holdings, argues that AI infrastructure risk has been routed away from…
